RAD-x closes its first transaction: IRD SA, a leading Swiss Diagnostic Imaging Centre
RAD-x announced that it has acquired IRD SA, located in Geneva, a leading diagnostic imaging provider. The sellers of IRD SA will reinvest part of the proceeds in the RAD-x holding and join Gilde Healthcare and RAD-x management as shareholders of the group. IRD SA will continue to be managed by its founding doctors and with the help of RAD-x will invest in expanding its diagnostic capacity.
With this transaction, RAD-x kick-starts its growth model and positions itself as a contender in the fast consolidating European diagnostic imaging market. RAD-x’ operational model is focused on delivering high quality diagnostic imaging services to patients throughout Europe and its growth strategy is funded by Gilde Healthcare, a leader in healthcare private equity. RAD-x is in discussion with several other medical imaging and healthcare groups to expands its presence across Europe; by achieving a critical mass quickly, RAD-x will achieve better conditions in procurement for heavy medical equipment.
Martin HARDENS, Co-founder and CEO of RAD-x: “I am pleased that we can welcome new partners in this early stage of development of RAD-x. This acquisition initiates our presence in the Swiss diagnostic imaging market. I look forward to working with the management team of IRD in delivering better healthcare for patients.”
Jasper van GORP, managing partner of Gilde Healthcare: “RAD-x is a fast-growing leader with a first-class management team. In a consolidating market, Gilde has been impressed by RAD-x’ commitment to quality and efficiency towards patients and clinicians. We are confident in its capacity to achieve outstanding growth in RAD-x’ core international markets.”
Frank KOLO, Co-founder and Medical Director of IRD SA: “I am confident that joining RAD-x will open new growth opportunities for IRD. Having a strong partner enables us to expand the diagnostic services we provide to our patients and referring doctors. RAD-x’ support for IRD to invest in two new state of the art MRI-machines and a refurbishment of our most important site is a proof of our joined commitment to continuous improvement in quality of care.”
About RAD-x
RAD-x a pan-European diagnostic imaging platforms at the forefront of the outpatient radiology market consolidation in France, Germany and Switzerland. RAD-x’ management team has many years of experience executing radiology and laboratory Buy & Builds. RAD-x’ imaging centres are managed by independent healthcare professionals, all being partners of the group and using shared services to continuously improve their market leading quality and efficiency. www.rad-x.eu
About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. Gilde’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Netherlands, Belgium and Germany. Gilde’s venture & growth capital fund invests in medtech, diagnostics, digital health and therapeutics. Since 2001 Gilde Healthcare has raised €800 million ($900 million) for its specialized funds.
https://gildehealthcare.com/
RAD-x Advisors for this transaction
– Financial and Tax DD: PricewaterhouseCoopers Switzerland (Martin JAMES, John TAVARES)
– Commercial DD: Abolon Group (Thimo SOMMERFELD)
– Legal DD and legal advice: Pestalozzi Attorneys at Law (Christian ROOS, Tom SCHAFFNER)
– Operational DD: NGI Group SA (Didier SENSEY, Bruno PERICART)